SalubRx Therapeutics Inc. is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders. SalubRx Therapeutics Inc. has developed a platform of selective inhibitors of the nitric oxide synthase (NOS) enzyme family, the enzyme which produces nitric oxide (NO). As the first company to be able to specifically target and inhibit the individual isozymes (nNOS, eNOS, iNOS), SalubRx can avoid any of the effects of blood pressure usually associated with eNOS providing the benefits of nNOS and iNOS alone or in combination as required. NO has been implicated in a wide variety of neurological disorders from migraine through to neurodegeneration. SalubRx’s selective NOS inhibitors may be especially suited to neurodegenerative diseases as a transformative symptomatic and disease modifying treatment. Parkinson’s Disease (PD) in particular may be particularly amenable to NOS based therapeutics. SalubRx Therapeutics Inc. has developed the NOS technology under an exclusive license from Knight Therapeutics.
SalubRx Therapeutics Inc. is dedicated to developing novel therapeutics targeting neuronal nitric oxide synthase (nNOS). The Company has issued and pending composition of matter patents on selective small molecule inhibitors of nNOS and dual n/iNOS. The focus of the Company's efforts is to continue to build upon this intellectual property asset and leverage it with product focused medicinal chemistry, biology and clinical development expertise to create a pipeline of proprietary single and dual-action small molecule nNOS inhibitors treatment of neurodegenerative diseases. SalubRx has a pipeline of clinical and preclinical NCE’s as clinical leads, back-ups and new developments. Characteristic profiles and properties: BCS 1, low COG’s, API stability up to 3 years, 90 day primate tox with minimal findings and safety in elderly patients.